People with AIDS may respond to a new drug in the form of a small protein known as T-20, which prevents the virus from binding to its target cells.

Call, S. . . . and M. Saag. 1999. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort. 39th Interscience Conference on Antimicrobial Agents and Chemistry. September. San Francisco.

Lalezari, J., et al. 1999. Sixteen week analysis of heavily pre-treated patients receiving T-20 as a component of multi-drug salvage therapy. 39th Interscience Conference on Antimicrobial Agents and Chemistry. September. San Francisco.

J. Lalezari
Quest Clinical Research
2300 Sutter Street, Suite 202
San Francisco, CA 94115

Michael S. Saag
University of Alabama, Birmingham
Department of Medicine
Division of Infectious Diseases
Birmingham, AL 35294-2050

From Science News, Vol. 156, No. 15, October 9, 1999, p. 236. Copyright © 1999, Science Service.